The number of weight-loss bariatric procedures has been on the increase, especially since the publication of NICE guidelines on obesity in which bariatric surgery was recommended as a treatment option for some patients. Following bariatric surgery, patients are restricted to a liquid diet and their medications are usually changed from solid dosage forms to unlicensed liquid formulations. This switch may not be necessary or may continue for longer than the clinical need and can have significant implications for the drug budget. This bulletin provides information for prescribers on the appropriate prescribing of liquid formulations for patients that have undergone bariatric surgery.
